Key Takeaways
- ATBS recovery drives the quarter: Destocking that suppressed volumes through calendar 2023 ended, pushing ATBS utilization from 65% to near 100% and setting up double-digit growth in FY25.
- New capacity is late, not lost: The ATBS expansion line will not start before December or January due to European equipment delivery constraints, delaying volume upside but not the demand thesis.
- VOPL is a FY26 story: The MEHQ Guaiacol plant was commissioned in March 2024, but meaningful revenue from the VOPL portfolio arrives only in H2 FY25, with peak ~₹500 crores still three years out.
- Margins are structurally capped at ~26%: Management expects EBITDA margins to stay in this range because butylphenols and antioxidants carry different margin profiles, and the product mix is not expected to change meaningfully.
- What to watch next quarter: Whether the ATBS expansion timeline firms up, antioxidants utilization climbs toward the 50% target, and any early revenue signals from the newly commissioned MEHQ Guaiacol plant.
ATBS: Recovery, Constraints & Expansion
- Destocking cycle resolved: Customers overbought in 2022 and sat on inventory through calendar 2023; by year-end inventory was at optimum levels, so normal consumption buying resumed, driving the Q4 volume recovery.
- High-purity demand creates a capacity pinch: Strong demand for higher-purity ATBS means less volume can be produced per unit of capacity, so the plant is effectively constrained even at close to 100% utilization.
- Expansion delayed by equipment deliveries: The new ATBS line will not start before December or January due to delivery constraints on equipment ordered from Europe, pushing the volume unlock further into FY26.
- Ramp-up is a multi-year process: After the new line is commissioned, management expects at least three years to reach full capacity utilization.
- Double-digit growth still expected in FY25: Despite the capacity constraint and expansion delay, management guided for double-digit ATBS sales growth in the next financial year, implying pricing or mix gains carry some of the load.
Vinati Saraf Mutreja: "Today, we are seeing good demand for the higher purity ATBS. When that is in demand, then you can produce less. There is capacity constraint."
VOPL Portfolio: Commissioned but Not Yet Contributing
- MEHQ Guaiacol plant live but in ramp-up: The plant was commissioned in March 2024; the company is still working on product testing, customer sampling, and enhancing yield and efficiency, so commercial volumes are not yet material.
- Revenue only from H2 FY25: Management expects revenue contributions of any significance from VOPL only from the second half of FY25, with FY25 sales pegged at maybe ₹50 crores, not even ₹100 crores, because other products get commercialized only by December or January.
- Peak revenue ~₹500 crores, three years out: At a 1:1 asset turnover assumption, peak revenue potential for VOPL is ~₹500 crores, and three years from today is a fair assumption to get there.
- Product pipeline extends beyond the first plant: The VOPL portfolio will eventually include the whole range of isoamylene derivatives (five to six new products), plus anisole-based products: MEHQ, Guaiacol, potentially BHA in the future, and 4-methoxyacetophenone used alongside PTB-Ester for Avobenzone manufacturers.
- Other VOPL products commissioning in H2 FY25: Anisole, 4-methoxyacetophenone, tertiary amyl alcohol and para tertiary amylphenol are expected to be commissioned in the second half of this financial year.
Vinati Saraf Mutreja: "…due to delivery constraints of some of the equipment that we have ordered from Europe the plant I do not think will start before December or January. That is what realistically it is looking like."
Butylphenols & Antioxidants: The Margin-Mix Story
- Butylphenols delivered ~₹300 crores in revenue with good growth seen during the year; an anti-dumping duty imposed on butyl phenol enabled a price improvement, though revenue also fluctuates based on input raw material prices.
- Peak revenue after the Veeral Additives merger is around ₹300-320 crores, with the anti-dumping duty potentially changing that ceiling upward.
- Antioxidants revenue was ~₹130 crores with value synergies growing from the doubly backward integrated plant, but demand remains weak and price erosion occurred over the last year due to product coming in from China and other places in a slow market.
- Utilization target is 50% this year, up from 25% last year; as the market recovers, pricing may improve, and the company believes it can be very competitive given double backward integration.
- R&D is adding more specialized, niche antioxidants that are lower volume but higher value, expanding the portfolio beyond the current offering.
- These two segments structurally cap blended margins: Butylphenols and antioxidants have different margin profiles from the core ATBS business, and since the product mix is not expected to change meaningfully, EBITDA margins are expected to stay around 26%.
Vinati Saraf Mutreja: "I expect to maintain or to see EBITDA margins in the range of 26% because this is how the product mix is going to stay going forward. Butylphenols, antioxidant businesses they have a different margin profile."
Competitive Position & China Risk
- No market share lost in any product: Management stated the company has not lost market share in any of its products, with the only product facing competition from China being antioxidants, where good domestic demand and double backward integration provide a cost shield.
- China is not seen as a major threat to most of the other product segments the company operates in, implying the ATBS and butylphenols franchises remain well-protected.
- Antioxidants pricing pressure is cyclical, not structural: Price erosion came from Chinese product entering a slow market; as the market recovers, pricing may improve, and the company's backward integration makes it competitive even at lower price points.
Vinati Saraf Mutreja: "I don't see China as a major threat to at least most of the other product segments that we are into."
New Product Strategy & Growth Algorithm
- Two to three new products added every year for the last five years, a cadence management intends to maintain: first butyl phenols and antioxidants, now the full VOPL range including isoamylene derivatives, and more niche antioxidants in the pipeline.
- Customized products basket has doubled revenue over four years to ~₹150 crores, though it remained flattish in FY24 vs FY23; good growth is expected in coming years.
- IBB and the niche Japanese-customer product basket remained unchanged this year and are expected to stay more or less the same in FY25, providing a stable base but no incremental growth.
- The 20% revenue CAGR ambition over three years is to be driven mainly by new products and existing products, with VOPL as the largest single contributor once it ramps.
Vinati Saraf Mutreja: "We keep adding two to three products every year. First three years, four years back we added butyl phenols and we added antioxidants. Now we will add the whole range of products in VOPL which also includes isoamylene derivatives, five, six new products."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| ATBS sales growth | Double-digit growth | FY25 |
| ATBS expansion completion | New line commissioned | Second half of FY25 (not before Dec/Jan) |
| ATBS new line full utilization | Full capacity utilization achieved | At least three years after commissioning |
| VOPL meaningful revenue | Revenue contributions of significance begin | H2 FY25 |
| VOPL FY25 sales | Maybe ₹50 crores, not even ₹100 crores | FY25 |
| VOPL peak revenue | ~₹500 crores (1:1 asset turnover) | ~3 years from today |
| VOPL other products commissioning | Anisole, 4-MAP, TAA, PTAP commissioned | H2 FY25 |
| Antioxidants capacity utilization | At least 50% utilization | FY25 |
| Revenue CAGR | ~20% | Over next 3 years |
| EBITDA margin | Maintain around 26% | Going forward |
| PAT growth | At least 20-25% higher than FY24 | FY25 |
| Butylphenols growth | Continue delivering growth | Next financial year |
| Customized products growth | Good growth expected | Coming years |
| IBB performance | Same figure as FY24 | FY25 |
| Niche product basket (Japanese customers) | Remain more or less the same | FY25 |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Total income | ₹560 cr, +23% QoQ from ₹457 cr in Q3 FY24 |
| EBITDA | ₹160 cr, +29% QoQ from ₹123 cr in Q3 FY24 |
| PAT | ₹104 cr, +30% QoQ from ₹77 cr in Q3 FY24 |
| Total income (full year FY24) | ~₹1,930 cr, -9% YoY from ~₹2,100 cr in FY23 |
| EBITDA (full year FY24) | ~₹509 cr, -18% YoY from ~₹620 cr in FY23 |
| PAT (full year FY24) | ~₹323 cr, -23% YoY from ~₹419 cr in FY23 |
| EBITDA margin guidance | ~26%, expected to be maintained going forward |
| Revenue CAGR guidance | ~20% over the next 3 years |
| PAT growth guidance (FY25) | at least 20–25% higher than FY24 |
| ATBS revenue contribution | ~32% of total revenue in FY24, similar in Q4 |
| ATBS global market share | 60–65%, unchanged |
| ATBS capacity utilization | close to 100% on existing capacity, up from 65% in the prior quarter |
| Butyl phenols sales (FY24) | ~₹300 cr |
| Butyl phenols capacity utilization | 65–70% in FY24, close to 100% in Q4 FY24 |
| Antioxidant business revenue (FY24) | ~₹130 cr |
| Antioxidant capacity utilization | ~25% in FY24, expecting at least 50% in FY25 |
| Capex incurred (FY24) | ~₹360 cr, across Vinati Organics and VOPL |
| Capex guidance (FY25) | ~₹550 cr, including subsidiary |
| VOPL total capex | ~₹500 cr |
| VOPL expected sales (FY25) | ~₹50 cr, meaningful revenue only from H2 FY25 |
| VOPL peak revenue potential | ~₹500 cr, achievable in 3 years |
| Solar power commissioned | ~33 MW |